recombinant human Hsp110-gp100 chaperone complex vaccine

We show that short hairpin RNA-mediated SRA silencing significantly enhances the immunogenicity of DCs that have captured chaperone vaccines designed to target melanoma (i.e., hsp110-gp100) and breast cancer (i.e., hsp110-HER/Neu-ICD)...Targeting SRA with this chitosan-siRNA regimen combined with the chaperone vaccine also leads to reprogramming of the tumor environment, indicated by elevation of the cytokine genes (i.e., ifng, il12) known to skew Th1-like cellular immunity and increased tumor infiltration by IFN-γCD8 CTLs as well as IL-12CD11c DCs. Given the promising antitumor activity and safety profile of chaperone vaccine in cancer patients, further optimization of the chitosan-siRNA formulation to potentially broaden the immunotherapeutic benefits of chaperone vaccine is warranted.

A fully recombinant human Hsp110-gp100 chaperone complex vaccine had minimal toxicity, measurable tumor responses at lower doses and produced peripheral CD8+ T cell activation in patients with advanced, pretreated melanoma. Combination with currently available immunotherapies may augment clinical responses.

A fully recombinant human hsp110-gp100 chaperone complex vaccine had minimal toxicity, measurable tumor responses at lower doses, and produced peripheral CD8+ T-cell activation in patients with advanced, pretreated melanoma. Future directions include combination with currently available immunotherapies and multiantigen vaccine development.

P1, N=10, Terminated, Roswell Park Cancer Institute | Suspended --> Terminated; Study was Suspended since 2018; PI decided to terminate.

P1, N=9, Suspended, Roswell Park Cancer Institute | Trial completion date: Dec 2019 --> Jun 2020